Bernstein downgraded Genmab (GMAB) to Underperform from Market Perform with a price target of DKK 1,000, down from DKK 1,580. The share price ...

Bernstein analyst Justin Smith downgraded Genmab A/S (0MGB – Research Report) to a Sell on March 28 and set a price target of DKK1,000.00. The ...

Investing.com -- Bernstein analysts have downgraded Genmab A/S (CSE: GMAB) to an "underperform" rating from "market perform,” in a note dated Tuesday. Shares of the Danish biotechnology company were ...

NASDAQ:GMAB opened at $18.82 on Tuesday. The company has a market capitalization of $12.45 billion, a PE ratio of 10.82, a P/E/G ratio of 2.65 and a beta of 0.98. Genmab A/S has a 52-week low of ...

Envestnet Portfolio Solutions Inc. reduced its holdings in Genmab A/S (NASDAQ:GMAB – Free Report) by 29.3% in the 4th quarter, according to the company in its most recent 13F filing with the ...

Shares of Genmab A/S (GMAB) fell this week after partner Johnson & Johnson (JNJ) unsurprisingly opted out of the deal to develop and commercialize GEN3014, Genmab’s next-generation CD38 HexaBody ...

Investing.com -- Genmab (CSE:GMAB) (NASDAQ:GMAB) announced on Monday, March 10, that Johnson&Johnson (NYSE:JNJ) has chosen not to proceed with the development of GEN3014 (HexaBody-CD38), a next ...

In a recent filing with the U.S. Securities and Exchange Commission, Danish biotech company Genmab (NASDAQ:GMAB) A/S (current market cap: $11.44 billion) has reported transactions as part of its ...

ADRs traded lower on Tuesday after Bernstein downgraded the Danish biotech to Underperform from Market Perform, arguing that its stock has yet to fully reflect the upcoming patent cliff for the ...